Inventor · disambiguated record
Jeng-Horng Her
Also filed as: HER JENG-HORNG
15 granted patents·11 pending applications·82 citations·filing 2001–2025
91Inventor score
Files withAP BIOSCIENCES INC13KALOBIOS INC3KALOBIOS PHARMACEUTICALS INC3MANCEBO HELENA S2ALLGENESIS BIOTHERAPEUTICS INC1
Top patents by PatentIndex Score
26 records- 0193US7981843B2Antibody specificity transfer using minimal essential binding determinantsKALOBIOS PHARMACEUTICALS INC·Filed 2005·Granted Jul 19, 2011·36 cites·14 claims
- 0285US9988611B2Protein inhibitors to complement and VEGF pathways and methods of use thereofAP BIOSCIENCES INC·Filed 2012·Granted Jun 5, 2018·10 cites·41 claims
- 0379US11780922B2Bifunctional proteins combining checkpoint blockade for targeted therapyAP BIOSCIENCES INC·Filed 2020·Granted Oct 10, 2023·1 cites·15 claims
- 0479US11299531B2Fusion protein comprising a ligand binding domain of VEGF and PDGFALLGENESIS BIOTHERAPEUTICS INC·Filed 2016·Granted Apr 12, 2022·2 cites·18 claims
- 0578US12312409B2Bispecific CD137-binding antibodies for T-cell activationAP BIOSCIENCES INC·Filed 2023·Granted May 27, 2025·0 cites·9 claims
- 0678US12304961B2PD-L1 and OX40 binding proteins for cancer regulationAP BIOSCIENCES INC·Filed 2023·Granted May 20, 2025·0 cites·19 claims
- 0777US11518984B2Protein inhibitors to complement and VEGF pathways and methods of use thereofAP BIOSCIENCES INC·Filed 2018·Granted Dec 6, 2022·2 cites·29 claims
- 0876US8178346B2GPCR expression vectorMANCEBO HELENA S·Filed 2010·Granted May 15, 2012·4 cites·24 claims
- 0976US7544477B2Circularly permutated, interaction-activated proteinsKALOBIOS INC·Filed 2001·Granted Jun 9, 2009·10 cites·7 claims
- 1072US2025346678A1OX40 Binding Proteins for Cancer RegulationAP BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 1172US2023322931A1Bifunctional Proteins Combining Checkpoint Blockade for Targeted TherapyAP BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 1271US2025270338A1Antibodies for t-cell activationAP BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 1370US7432063B2Methods for affinity maturationKALOBIOS PHARMACEUTICALS INC·Filed 2003·Granted Oct 7, 2008·11 cites·26 claims
- 1466US11643470B2PD-L1 and OX40 binding proteins for cancer RegulationAP BIOSCIENCES INC·Filed 2020·Granted May 9, 2023·0 cites·27 claims
- 1566US2025154273A1PD-L1 and OX40 Binding Proteins for Cancer RegulationAP BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 1664US11725058B2CD137 antibodies for T-cell activationAP BIOSCIENCES INC·Filed 2020·Granted Aug 15, 2023·0 cites·12 claims
- 1762US7335478B2Reactivation-based molecular interaction sensorsKALOBIOS PHARMACEUTICALS INC·Filed 2002·Granted Feb 26, 2008·5 cites·29 claims
- 1860US2024400717A1Antibody Binding to CHI3L1 for Treating CancerUNIV NAT CHENG KUNG·Filed 2022·Application pending·0 cites
- 1959US2024391976A1Bi-Functional Fusion Proteins to Complement Pathways and Method of Inhibiting Bone ResorptionAP BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2059US2025026841A1Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapyAP BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2157US7781209B2GPCR-expressing cell linesMULTISPAN INC·Filed 2006·Granted Aug 24, 2010·1 cites·33 claims
- 2250US8148110B2Detection of molecular interactions by β-lactamase reporter fragment complementationBLAU HELEN M·Filed 2002·Granted Apr 3, 2012·0 cites·37 claims
- 2347US2005008625A1Antibody affinity engineering by serial epitope-guided complementarity replacementKALOBIOS INC·Filed 2004·Application pending·0 cites
- 2441US2002155502A1Affinity maturation by competitive selectionHORIZON BIOTECHNOLOGIES INC·Filed 2001·Application pending·0 cites
- 2539US2004038317A1Breakpoint fusion fragment complementation systemKALOBIOS INC·Filed 2003·Application pending·0 cites
- 2634US2012219968A1GPCR Expressing Cell Lines and AntibodiesMANCEBO HELENA S·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jeng-Horng Her files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →